Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response
复制标题
DOI：
10.1080/17476348.2019.1676734
复制
发表时间：
2019-10-18
影响因子：
3.9
通讯作者：
Schiappoli, Michele
中科院分区：
文献类型：
--
作者：
Caminati, Marco;Cegolon, Luca;Schiappoli, Michele
背景：很少有研究提供美泊利单抗疗效和安全性的真实证据。我们的目的是评估美泊利单抗在日常临床实践中对重度嗜酸性粒细胞性哮喘的疗效。研究设计与方法：对RINOVA（意大利韦内托地区重度哮喘管理跨学科网络）数据库中纳入的患者进行了研究。在美泊利珠单抗治疗期间，评价了血嗜酸性粒细胞计数、1秒用力呼气量、占预计值的百分比（FEV1%）、呼出气一氧化氮分数（FeNO）、哮喘控制试验（ACT）、口服类固醇（OCS）摄入量和急性发作率。结果：69例患者（平均年龄：55.1？60.9%女性）。一个显着的改善，检测到在一个月的血嗜酸性粒细胞（中位数水平在基线：710/？l;？620/？l，p
Background: Few studies have provided real-world evidence of mepolizumab efficacy and safety. We aimed to evaluate mepolizumab for severe eosinophilic asthma in daily clinical practice. Research design and methods: Patients included in the RINOVA (Interdisciplinary Network for the management of severe asthma in Veneto region, Italy) database were investigated. Blood eosinophil count, forced expiratory volume in 1 second, % of predicted (FEV1%), fractional exhaled nitric oxide (FeNO), asthma control test (ACT), oral steroid (OCS) intake, and exacerbation rate were evaluated during mepolizumab treatment. Results: 69 patients were enrolled (mean age: 55.1?years; 60.9% females). A significant improvement was detected at one month with respect to blood eosinophils (median level at baseline: 710/?l; ?620/?l, p